Editas Medicine Inc at Barclays Virtual Gene Editing & Gene Therapy Summit Transcript
Welcome, everyone. Thank you, and welcome. Joining us next presenting company is Editas Medicine. With me, we have Cindy Collins, President and Chief Executive Officer; Charlie Albright, our Chief Scientific Officer; Michelle Robertson, Chief Financial Officer; Mark Mullikin, VP of Finance and Investor Relations. With that, I will hand over to Cindy.
Thank you, Gena. So good morning, everyone. Thank you for joining us here today.
Pushing forward the boundaries of medicine entails risk as well as great progress. This slide tells you all about the risk. At Editas, we strive to make differentiated transformational medicines for diseases of high unmet need. To accomplish this objective, we are pursuing 2 strategic pillars, in vivo CRISPR medicines and ex vivo cell medicines. In our in vivo CRISPR medicine portfolio, we are able to leverage our proprietary smaller Staph. aureus Cas9 enzyme for more efficient and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
